2nd Faculty of Medicine Charles University Prague Czech Republic

Abteilung Hämatologie Onkologie Klinik für Innere Medizin 2 Jena University Hospital Jena Germany

CLIP Department of Pediatric Haematology and Oncology 2nd Faculty of Medicine and Faculty Hospital Motol Charles University Prague Czech Republic

Institute of Hematology and Blood Transfusion Prague Czech Republic

Institute of Pathological Physiology 1st Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Hochhaus A, Kim DW, Cortes JE, Sasaki K, Mauro MJ, Hughes TP, et al. Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1(T315I) treated with at least 2 prior TKIs: Phase 1 final results. Leukemia PubMed PMC

Hochhaus A, Réa D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023;37:617–26. PubMed PMC

Cortes JE, Sasaki K, Kim DW, Hughes TP, Etienne G, Mauro MJ, et al. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after 1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia. 2024;38:1522–33. PubMed PMC

Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, et al. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. N Engl J Med. 2024;39:885–98. PubMed

Curik N, Laznicka A, Polivkova V, Krizkova J, Pokorna E, Semerak P, et al. Combination Therapies with Ponatinib and Asciminib in a Preclinical Model of Chronic Myeloid Leukemia Blast Crisis with Compound Mutations. Leukemia. 2024;38:1415–8. PubMed PMC

Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017;543:733–7. PubMed

Piazza RG, Magistroni V, Gasser M, Andreoni F, Galietta A, Scapozza L, et al. Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib. Leukemia. 2005;19:132–4. PubMed

Ong F, Kim K, Konopleva MY. Venetoclax resistance: mechanistic insights and future strategies. Cancer Drug Resist. 2022;5:380–400. PubMed PMC

Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I, et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med. 2000;191:977–84. PubMed PMC

Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K, et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood. 2005;105:3303–11. PubMed

Leonard JT, Rowley JS, Eide CA, Traer E, Hayes-Lattin B, Loriaux M, et al. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. Sci Transl Med. 2016;8:354ra114. PubMed

Short NJ, Nguyen D, Jabbour E, Senapati J, Zeng Z, Issa GC, et al. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial. Lancet Haematol. 2024;11:e839–e849. PubMed PMC

Short NJ, Konopleva M, Kadia T, Kebriaei P, Daver N, Huang X, et al. An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol. 2021;96:E229–32. PubMed PMC

Gleixner KV, Filik Y, Berger D, Schewzik C, Stefanzl G, Sadovnik I, et al. Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 (T315I)-compound mutations. Am J Cancer Res. 2021;11:4470–84. PubMed PMC

Sponseiler I, Bandian AM, Pusic P, Lion T. Combinatorial treatment options for highly resistant compound mutations in the kinase domain of the BCR::ABL1 fusion gene in Ph-positive leukemias. Am J Hematol. 2024;99:E9–11. PubMed